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Summary.- The effects of adoptive transfer of spleen cells from tumour-bearing
mice on the growth of Moloney murine sarcoma virus (M-MuSV)-induced primary
tumours in BALB/c mice were studied. The effects were in2 directions, depending on
the time of lymphocyte inoculation; when spleen cells from tumour-bearing mice
12 days after M-MuSV inoculation were inoculated into recipient mice before M-MuSV
inoculation, the appearance of tumours was significantly delayed and their incidence
was reduced, whereas whenthese lymphocytes were inoculated after thedevelopment
of tumours in recipient mice, tumour growth was significantly enhanced. The data
indicated that these inhibiting and enhancing effects were mediated mainly by T
cells. The mechanisms of the paradoxical effects were investigated.
MANY investigators in tumour immun-
ology have reported that tumours possess
specific antigens which are recognized by,
and induce an immune response in the
host, as detected in a variety of in vitro
systems. However, despite these immune
responses observed in vitro, most tumours
grow progressively to kill the host animal.
Hypotheses which have been proposed to
explain the discrepancies between in vitro
and in vivo results include;
(i) the presence of specific serum block-
ing factors in tumour-bearing mice (Hell-
strom and Hellstrom, 1969; Hellstrom
and Hellstrom, 1970; Sjogren and Hell-
strOm, 1971; Jurin and Suit, 1974;
Kilburn et al., 1976; McMaster et at.,
1977);
(ii) suppressor-cell activity against spe-
cific immune lymphocytes (Glaser et at.,
1975; Fujimoto et al., 1976a, 1976b) or
non-specific lymphocytes (Kirchner et al.,
1974; Gorczynski, 1974; Kirchner et al.,
1975); and
(iii) cell-mediated enhancement of
tumour growth (Ilfeld et al., 1973; Umiel
and Trainin, 1974; Small and Trainin,
1976; Gabizon et al., 1976).
To analyse further the possibilities
mentioned above, itisnecessary to develop
experimental systems which permit the
direct investigation ofthe in vivo effects of
immune lymphocytes on tumour growth
in a form as close as possible to the
naturally occurring disease. Our experi-
ments attempted to approximate to such a
system, and involved adoptive transfer
of lymphocytes to mice bearing Moloney-
murine sarcoma virus (M-MuSV)-induced
primary tumours and observation of the
resulting modulation in the pattern of
tumour growth. The advantages of using
the M-MuSV-induced primary tumour
system in studying adoptive lymphocyte
transfer were:
(i) by selecting the conditions, we
could produce sarcomas in animals with
growing patterns suited to the purpose of
a particular experiment;
(ii) we could study the effect ofimmune
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response not only on the growth of
tumours but also on the appearance of
tumours, following viral carcinogenesis,
which cannot be studied by using already
malignantly transformed transplanted
tumours;
(iii) in virus-induced primary tumours
(which, contrary to chemically induced
primary tumours, share tumour-specific
antigens) we could investigate the effects
of lymphocytes from one animal on the
growth of primary tumours in other
animals;
(iv) we could compare our in vivo
results with those in the literature on in
vitro experiments with M-MuSV-induced
tumours; and
(v) an autochthonous system, such as
the M-MuSV-induced primary tumours we
selected, is a closer model to human
malignancies than a syngeneic trans-
planted tumour system.
In the present study, we observed two
mutually antagonistic effects of lympho-
cytes from tumour-bearing mice on M-
MuSV-induced tumours. That is, when we
inoculated these lymphocytes into mice
before the virus inoculation, appearance
of tumours was delayed, and their inci-
dence was reduced (inhibiting effect).
However, when we inoculated these lym-
phocytes into mice which had already
developed tumours, they enhanced tumour
growth (enhancing effect). We investigated
the nature of the effective cell population
as well as the kinetics ofthese paradoxical
effects.
MATERIALS AND METHODS
Mice.-Female BALB/c mice wereobtained
from the Mammalian Genetics and Animal
ProductionSection, NationalCancerInstitute,
Bethesda, Maryland.
Induction of sarcomas-.One-tenth ml of
107 focus-forming units (FFU)/ml M-MuSV
(No. 244, the gift of Dr A. F. Gazdar, NCI) at
1:20 dilution was inoculated i.m. into the
hind leg of 7- to 9-week-old mice to produce
tumours as shown in Fig. 1.
Measurement of tumour size.-The maxi-
mum diameter oftumours was measured by a
slide caliper 2-3 times a week. Tumour size
was calculated by subtracting the mean
diameter of normal legs (5 5 mm) from the
maximum diameter of the tumour. The mean
tumour size was calculated from these
records for each group (8-15 mice/group).
When an animal died of tumour growth, the
last available record of tumour size was used
in the calculations.
Tumour incidence.-Although most
tumours grow progressively, reaching about
20 mm in diameter, some of those less than
12 mm in diameter occasionally regressed.
Therefore, only mice with tumours larger
than 12 mm were considered as tumour-
positive.
Transplanted tumours.-5 x 106 methyl-
cholanthrene-induced BALB/c sarcoma
(MCA-15B) cells (the gift of Dr C. W. Boone,
NCI) were inoculated i.m. into the hind leg of
mice and the tumour size was recorded as
above.
Preparation of spleen cells.-Spleens from
tumour-bearing and normal mice were re-
moved aseptically, minced with sterile
scissors, mashed with the flexible tip of the
plunger of a disposable plastic syringe, and
suspended in Earle's balanced salt solution
(EBSS). After debris was removed by
filtering the tissue suspension through an
80-gauge steel mesh, free cells were sedimen-
ted by centrifugation at 200 g for 10 min. To
eliminate red blood cells, 108 spleen cells/ml
were incubated in tris-buffered 0-153 M
NH4Cl, pH 7-2, at 4°C for 7 min with periodic
agitation, and the cells were washed twice in
EBSS. To remove macrophages, spleen cells
were suspended in McCoy's 5A medium
(Grand Island Biological Co., Grand Island,
N.Y.) containing 10% heat-inactivated foetal
calf serum (FCS), transferred to a culture
flask at a concentration of 1-2 x 106 cells/cm2
of plastic surface, and incubated at 37°C in a
5% CO2 atmosphere for 2 h. Nonadherent
cells were collected and washed once in the
medium. To separate lymphocyte subpopula-
tions, spleen cells were fractionated by
passage over nylon-wool columns in a pro-
cedure modified from that of Julius et al.
(1973). Briefly, 109 prepared spleen cells
per 5 ml medium were loaded on a nylon-
wool column packed in a 35 ml disposable
syringe; the nylon wool was preincubated and
prewashed with warm medium containing
10% FCS. After incubation at 37°C in a 5%o
CO2 for 1 h, nonadherent cells were eluted
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FiG. IA.-Progressor M-MuSV-induced sarcoma, 12 days after M-MuSV inoculation. The tumour
consists of interlacing bundles of spindle-shaped cells and collagen fibres. The muscle bundles are
infiltrated and destroyed by tumour cells (left below), H. and E. x 30.
FIG. IB.-Tumour cells with large and hyperchromatic nuclei show a remarkable degree of
pleomorphism and atypism. H. and E. x 300.
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with 80 ml medium at a rate of45 drops/min.
Adherent cells were recovered by taking the
nylon wool out of the syringe and squeezing
it with sterile forceps and with the syringe
plunger.
By immunofluorescence assays, using anti-0
serum and immunofluorescent antibodies
against mouse IgG (Hyland Lab, LosAngeles,
Ca.), the nonadherent cell population con-
tained 77-81% O-C3H-positive thymus-
dependent cells (T cells), 1-12% surface-
immunoglobulin positive marrow-dependent
cells (B cells), and 11-18% cells which were
negative for both markers. The adherent cell
population consisted of0-3% 6-C3H-positive,
86-93% Ig-positive, and 5-14% nonfluores-
cent cells. A T-cell-depleted cell population
was prepared by treating the spleen cells with
AKR anti-9-C3H serum and rabbit comple-
ment. After elimination of RBC, 108 spleen
cells/ml were incubated with 1:16 diluted
AKR anti-O-C3H serum (titre 1:256) at room
temperature for 30 min, centrifuged and re-
suspended in 1:6 diluted rabbit complement
preabsorbed with an equal volume of benzo-
pyrene-induced C57BL/6 lymphoma (EL4)
cells. After incubation at 37°C for 30 min
with constant rocking, cells were washed
twice with EBSS.
Adoptive transfer of lymphocytes.--02 ml
of serial numbers (1 x 106-2 x 108) oflympho-
cytes were inoculated i.p. into tumour-
bearing or normal mice. In control groups,
103-105 FFU of M-MuSV or 105-107 of 0I1%
formalin-fixed Moloney murine leukaemia
virus (M-MuLV)-induced BALB/c lymphoma
(LSTRA) cells were inoculated i.p. into
mice.
Infective centre assay.-The infective centre
assay was performed by a procedure slightly
modified from that described by Kawashima
et al. (1976). Briefly, 105 D-56 cells (a mixture
of sarcoma-positive leukaemia-negative and
outbred Swiss/3T3 lines) and BALB/3T3
cells (BALB/c embryonic fibroblasts) in
McCoy's 5A medium supplemented with 10%
FCS, 0.1 mg/ml Gentamicin (Schering Co.,
Kenilworth, N.J.) and 2-5 jg/ml Fungizone
(Grand Island Biological Co.) were seeded in a
60 mm diam. Petri dish. On the following day,
after treatment of the cells with 25 [kg/ml
DEAE-Dextran for 45 min, serial dilutions of
2000 rad-irradiated spleen cells from normal
or tumour-bearing mice or LSTRA cells were
added to each plate. Media were changed
every 2 days. Six days later, the number
offoci or plaque formations was counted with
an inverted microscope.
Neutralization test.-Appropriate concen-
trations of virus in 0-4 ml of medium were
mixed with 0 4 ml of 1:8 diluted test serum.
The mixture was incubated at room tempera-
ture for 60 min and then at 4°C for 30 min
with periodical shaking. A volume of 0-2 ml
of this mixture was then added to a plate in
which D-56 cells had been seeded on the
previous day and treated with DEAE-
Dextran before the test. The focus-forming
activity of the remaining virus was deter-
mined 6 days after incubation. The ratio
(V/Vo) was the surviving fraction of virus.
RESULTS
Typical growth patterns of M-MuSV-
induced primary sarcomas
As has been stated elsewhere (Kirchner
et al., 1974; Herberman et al., 1974), there
are two types of M-MuSV: progressor and
regressor viruses. While regressor-M-
MuSV-induced sarcomas regress 20-30
days after virus inoculation ofthe animals,
60-80% of the progressor-M-MuSV-in-
duced tumours grow progressively to kill
the host. Fig. 2 shows 2 types of growth
patterns of progressor-M-MuSV-induced
sarcomas in female BALB/c mice. When
the virus was inoculated into young mice
(4-6 weeks old) tumours became detect-
able at 6-7 days later and the tumour size
reached the first peak on Days 12-13. The
tumours stopped growing for 5-6 days
and then grew progressively. They reached
a maximum size around Day 50 and the
animals started dying. For convenience,
the 4 stages ofgrowth in this fast-growing
system may be designated as follows: (i)
1st progressive stage, (ii) regressive stage,
(iii) 2nd progressive stage, and (iv)
plateau stage (as in Fig. 2).
When the virus was inoculated into
adult mice (7-9 weeks old) tumours
regressed more conspicuously after the
first peak, then stayed the same size for
2 weeks, until they started to grow again
around Day 35. The stages of this slow-
growing tumour system may be desig-
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FIG. 2. Typical growth curves of Moloney
murine sarcoma virus (M-MuSV)-induced
sarcomas in young and adult female
BALB/c mice. 4-6-week-old (young) mice
(solid line) and 7-10-week-old (adult) mice
(broken line) were inoculated i.m. with
M-MuSV (5 x 104 FFU/mouse). The results
are mean values of 5 grouips (10-15 mice/
group). I. 1st progressive stage, II.
regressive stage; III. 1st plateau stage;
IV. 2nd progressive stage; and V. 2nd
plateau stage. Parentheses: No. of mice
with tumours/No. inoculated.
nated as follows: (i) 1st progressive stage,
(ii) regressive stage, (iii) 1st plateau stage,
(iv) 2nd progressive stage, and (v) 2nd
plateau stage. The size of individual
tumours in young and adult mice was
similar, but since the incidence of tumours
in young mice was higher (78%) than that
in adult mice (66%), the mean tumour
size was larger in the young mice (see
Fig. 2). In the following study, unless
otherwise stated, the same lot of virus
preparation (progressor) and 7- to 9-week-
old mice were used for the observation of
tumour growth, and 5- to 6-week-old
mice were used as the source of spleen
cells.
Adoptive transfer of spleen cells: weekly
inoculations
Starting at 1 week after the virus inocula-
tion, the adult tumour-bearing mice
received 4 weekly i.p. injections of 1-
2 x108 spleen cells from normal (NS) or
tumour-bearing mice which had been
inoculated with M-MuSV 12 days pre-
viously (12S) (Fig. 3). The growth patterns
Days after M-MuSV inoculation
FIG. 3.-Adoptive transfer of spleen cells:
weekly inoculations. 10 mice in each group
received weekly inoculations of 12S (see
Materials and Methods) lymphocytes
(Z O DC:), NS lymphocytes (O- - -O)
(1-2 x 108 cells/mouse) or medium only
(0 0 *). Arrows indicate the time of
lymphocyte inoculation. In parentheses:
No. of mice with tumours/No. inoculated
with M-MuSV.
oftumours in the mice inoculated with NS
lymphocytes did not differ from that of
mice inoculated with medium only. On
the other hand, the tumour growth curve
of mice inoculated with 12S lymphocytes
showed a low peak followed by deep
regression for the first 20 days. Tumours
of this group of mice, however, grew
progressively from Day 20, without a 1st
plateau stage, and attained the 2nd
plateau stage 10 days earlier than other
groups (P<0-01 at Days 31-38 for mean
tumour size).
Adoptive transfer of spleen cells: one-shot
inoculation after, with, or before virus
inoculation
To evaluate the effect on tumour growth
of 12S lymphocytes transferred at different
stages, 8 X 107 NS or 12S lymphocytes
were inoculated into mice 1 week before,
at the same time as, or 1 week after M-
MuSV inoculation. Pairs of mice with
identical tumour size were divided into
2 groups, so that each group consisted of
the same numbers of mice with the same
tumour size (8 mice per group). 12S
lymphocytes inoculated 1 week after virus
inoculation enhanced tumour growth
-
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FiC'. 4. Adoptive transfer of spleen cells:
one-shot inoculation. 1 week after (A), at
the same time as (B), and I week before (C)
M-MuSV inoculation, 8 mice in each group
receivedL12S H)orNS (O - )
lymphocyte inoculation (8 x 107 cells/
mouse). Arrows indicate the time oflympho-
cyte inoculation. In parentheses: No. mice
with tumours/No. inoculated with M-MuSV.
significantly (enhancing effect) (Fig. 4A,
P< 005 at Day 18 and thereafter for mean
tumour size). Fig. 4B shows that no
significant effect was observed when 12S
lymphocytes were transferred with the
virus inoculation. But transfer of 12S
lymphocytes 1 week before the virus
inoculation delayed tumour appearance
and reduced tumour incidence (inhibiting
effect) resulting in a reduced mean tumour
size (Fig. 4C, P<0 05 at Days 11-26 for
mean tumour size).
Dose-response test
Next we conducted experiments to
study dose effect of 12S lymphocytes on
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FI(.w. 5.-Adoptive transfer of spleen cells:
(lose iesponse to i.p. inoculation. 10 mice
in each group received 128 lymphocyte
inoculation 1 week before (A) or I week
after (B) M-MtuSV inoctulation. Dose in A
(X106) L O, 50; * - *, 25;
A - A, 5; A A, I cells/mouse.
Dose in B ( x 106): H H, 200;
U-- U 100; A-- A, 50;
A *, 10 cells/mouse. 0 --- 0,
me(lium only. Arrows indicate the time of
lymphocyte inoculation. In parentheses:
No. mice wNith tumours/No. inoculated with
M-AMuSV.
tumour growth. For the inhibiting experi-
ment, 50 5-week-old mice were separated
into 5 groups. One week before M-MuSV
inoculation, each group was inoculated i.p.
with 1 X 106-5 x 107 12S lymphocytes or
with medium only (Fig. 5A). Since the
fast-growing tumour system demonstrated
the inhibiting effect more clearly than the
slow-growing one, young mice were used.
106 12S lymphocytes was sufficient to show
the inhibiting effect (P<0-01 at Day 12
onwards for mean tumour size and P<
0 05 at Day 18 onwards for tumour
incidence); the effect of inhibition in-
_
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creased with the number of inoculated
lymphocytes.
In the experiments to study enhance-
ment of tumour growth, 75 7- to 8-week-
old mice received virus inoculations. Since
it was necessary to choose mice bearing
tumours whose size was within a narrow
range for valid statistical analyses, 50 out
of 75 mice bearing tumours of 9-13 mm in
diameter were selected 8 days after virus
inoculation, divided into 5 groups, and
each animal received 1 X 107-2x108 12S
lymphocytes or 0-2 ml of medium i.p.
To demonstrate clearly the enhancing
effect on tumour growth by 12S lympho-
cytes, the slow-growing tumour system,
which used adult mice, was used. Signifi-
cant enhancement of tumour growth was
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Fi('. 6.-Adoptive transfer of 12S lympho-
cytes pturifedl on nylon-wool columns.
15-20 mice in each group receive(d 2 x 106
lvmphocytes/mouse 1 week before (A) andl
108 lymphocytes/mouse 1 week after (B)
Al-MuSV inoculation. non-
adlherent cells; A - A-, adherent cells;
O0- 0, nonselparatedl cells; 0 - - - , me(litum only. Arrows indicate the time of
lymphocyte inoculation. In parentheses:
No. mice wvith tumours/No. inoculated with
M-A1ItSV.
observed in mice which received a high
number of 12S lymphocytes (Fig. 5B,
P<0 05 for mean tumour size at Days
16-44 in mice inoculated with 2 x 108 cells
and at Days 23-53 in mice inoculated with
5x107 cells).
Adoptive transfer of 128 lymphocytes puri-
fied on nylon-wool column
To study whether these tumour-en-
hancing and tumour-inhibiting effects were
mediated by the same population of
lymphocytes, we fractionated 12S lympho-
cytes on nylon-wool columns and used
them in inhibiting and enhancing experi-
ments. In inhibiting experiments, the
non-adherent cell population (77-81% T
cells, 1-1200 B cells) demonstrated a
clear inhibiting effect (Fig. 6A, P<0 01
at Day 13 for tumour incidence, P<0 05
at Day 11 onwards for mean tumour size),
but the adherent cell population (0-300
T cells, 86-93% B cells) had a low but still
significant inhibiting effect (P<0 05 at
Days 11-22 for mean tumour size). In the
enhancing experiments, the non-adherent
cell population mediated a significantly
greater enhancing effect than the adherent
cell population (Fig. 6B, P<0 05 at Day
33 onwards for mean tumour size).
When the 12S lymphocytes were treated
with anti-6 antibody and complement, the
results were consistent with those obtained
with cells separated on nylon-wool col-
umns. The T-cell-depleted population
exerted a smaller effect in both enhancing
and inhibiting experiments than 12S
lymphocytes treated with complement
alone (data not shown).
Effect of 12S lymphocytes on antigenically
distinct tumour cells
To see whether the effects of lympho-
cytes were specific or non-specific, these
experimental systems were applied to an
antigenicallydistincttransplanted tumour.
Neither enhancement nor inhibition ofthe
growth of methylcholanthrene-induced
BALB/c fibrosarcoma (MCA-15B) was
observed with 12S lymphocytes (Fig. 7).
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FIG. 7.- Effect of spleen cells on the grow%th
of MCA-15B cells. 10 mice in each group
received 2 x 106 lymphocytes per mouse
I week before (A) or 8 x 107 lymphocytes
per mouse 1 week after (B) MCA-15B cell
inoculation. C O, 128 lymphocytes;
A-- -A, NS lymphocytes; O --- O,
control (medlium only). Arrows indicate the
time of lymphocyte inoctulatioin. In
parentheses: No. mice with tumours/No.
inoculated with M-MuSV.
Infectious centre assoay of 128 lymiphocytes
The possibility of virus infection in 128
lymphocytes was examined by the infec-
tious-centre assay. As shown in Table I,
low but significant amounts of leukaemia
virus (20-40 plaque-forming units (PFU)/
106 cells) and sarcoma virus infections
(10-40 FFU/106 cells) were observed with
12S lymphocytes. However, the T-cell-
rich population separated on nylon wool
(T cells probably being the main effector
cell in inhibiting tumour growth) showed
a significantly lower amount of infection
(leukaemia virus, 10-20 PFU/106 cells;
sarcoma virus, 5-20 FFU/106 cells) than
the B-cell-rich population (leukaemia
virus, 40-50 PFU/1 x 106 cells; and sar-
coma virus, 10-60 FFU/I x 106 cells)
(P<0 01-0 05 for Expts 2 and 3).
Effect of virus and lymphorna-cell inocula-
tion on tumour growth
The effects of inoculation of virtus or of
antigenically related lymphoma cells
(LSTRA) on M-MuSV-induced tumour
growth were studied, to see whether the
effects of 12S lymphocytes were caused by
virus infection of these lymphocytes. The
inoculation of the appropriate concentra-
tion of M-MuSV (1 04 FFU/mouse) inhibi-
ted tumour growth, but no enhancing
effect was observed. When LSTRA (M-
MuLV-induced BALB/c lymphoma) cells
were fixed in 0.10% formalin for 1 week
(Kudo et al., 1974), washed x4 in phos-
phate-buffered saline (PBS) andinoculated
TABLE I. Virus Release from LSTRA Cells and from Spleen Cells of Normal
and Tumour-bearing Mice: Results of Infectious-Centre Assay
No. of focus or plaque fortnation/106 cells- s(..
Normal
Expt. spleen
Nonadlherent
128 spleen* 12St
Adherent
12St
LSTRA P (Noniadl
( x 104) <Ad)
1 41-54 6-4
D-56 2 0-6+±03§ 38- I 5 5-5 16-8±-3-1 50-1 _ 4-1 1-7 ±0 2 <0-001
3 24-7±1 5 7-3 -- 2-1 42-7 2-1 2-9±0 -9 <-0-001
1 13 5±4-9
BALB/3T3 2 0-5±0 4 37-1-< 4-1 18-0± 2-3 62-5 7 -0 < 0-001
3 8-0±1-7 3 -3-2 -5 9-7 L4-0 <0-05
* 12S spleen lymphocytes from tumour-bearing mice inocuilated 12 clays previously wvith MM-Autis5V.
t Consisting essentially of T cells.
I Consisting essentially of B cells.
§ Plaque-forming unit s.d.
lFocus-forming unit±s.d.
Indicator
cells
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TABLE II.-Detection of Neutralizing Antibody Activity against M-MuSV with Serumn
from Mice which Received M-MuSV or Medium only after Inoculation with 12S or NS
Lymphocytes N t (V/Vo)
Serum source
NS*
NS+M-MuSVT
12S 11
12S+M-MuSV¶I
Neutralization titre (V/Vo)
Time after lymphocyte inoculation (weeks)
A
2 3 4
0-97 (0-07)t 0-72 (<0-01) 0-86 (0 21) 0-78 (0 04)
( 0 54 (0-01) 0-82 (0-16) 0-69 (0 25)
0 * 96 (0* 13) 0*56 (0* 15) 0 * 71 (0*34) 0 13 (0 10)
) 0-60 (0 07) 0-66 (0 08) 0 23 (0 09)
5
0-98 (<0(01)
0-22§(0-01)
0 (<0 01)
0 19 (0 02)
* Mice which received normal spleen lymphocytes (NS).
t No. foci in test plate/No. foci in control plate (s.d.).
t Mice which received M-MuSV inoculation 1 week after NS inoculation.
§ Underlined figures are significantly different from NS group, P < 0-01.
11 Mice which received spleen lymphocytes from tumour-bearing mice inoculated 12 dlays pIreviously with
M-MuSV (12S).
T Group which received M-MuSV inoculation 1 week after 12S inoculation.
i.p. into tumour-bearing or normal mice,
neither enhancement nor inhibition was
observed (data not shown).
Neutralization test
Neutralization tests were performed to
detect neutralizing antibody against M-
MuSV in serum of mice inoculated with
12S lymphocytes. Ten mice received 12S
or NS lymphocytes (2 x106 cells/mouse),
and 5 mice in each group were inoculated
i.m. with M-MuSV a week after the
lymphocyte inoculation. Serum from mice
receiving 12S lymphocytes demonstrated
earlier neutralizing-antibody activity than
that from mice receiving NS lymphocytes
(Table II).
DISCUSSION
The data presented in this paper clearly
demonstrate the existence of lymphocyte
population(s) in mice with M-MuSV-
induced primary tumours, which either
enhanced or inhibited tumour growth,
depending on the stages oftumour growth
atwhich thelymphocytes weretransferred.
If lymphocytes collected 12 days after
M-MuSV inoculation (designated 12S in
our experiments) were inoculated before
virus inoculation, tumour appearance was
delayed and tumour incidence was reduced
(inhibiting effect). If the same lympho-
cytes were inoculated after the develop-
ment of sarcomas, especially early in
tumour growth, significant enhancement
of tumour growth was observed (en-
hancing effect). Furthermore, the results
indicate that these effects were mediated
mainly by the nylon-wool non-adherent,
0-bearing T-cell population.
Why did the same subpopulation of
lymphocytes manifest opposite activities
when they were inoculated at different
stages of tumour growth? Our results
may be attributed to a discrepancy
between the activity of lymphocytes in
vivo and in vitro. If lymphocytes with
tumour-enhancing activity were converted
to tumour-inhibiting lymphocytes after
their transfer into a recipient animal,
inhibition of tumour growth would be
observed when the virus was inoculated
after the conversion. In vitro evidence
suggests that spleen cells 12 days after
M-MuSV inoculation are in the eclipse
stage, as demonstrated by decreased
cytotoxic activity against syngeneic M-
MuSV- or M-MuLV-induced tumour cells
(Hellstrom and Hellstrom, 1969; Kirchner
et al., 1974). Two weeks after this stage,
however, the lymphocytes regain their
cytotoxic activity, suggesting a conversion
of lymphocyte activity. Another possi-
bility is that the particular expression of
lymphocyte activity depends on the
condition of the host animals. In contrast
to transplanted tumours, the M-MuSV-
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induced primary tumours must undergo
transformation by virus beforethetumours
start growing. Thus the inhibiting effect
of 1 2S lymphocytes may be directed only
against the sarcoma virus, and the
enhancing effect may be directed against
the transformed tumour cells.
Another relevant question is whether
these enhancing and inhibiting effects are
mediated by a single subpopulation of T
lymphocytes. Spleen cells from tumour-
bearing mice can be fractionated by means
of velocity sedimentation into subpopula-
tions capable of inhibiting or enhancing
tumour growth (Small and Trainin, 1976).
It is conceivable that 2 lymphocyte sub-
populations with conflicting activities co-
exist in the 12S lymphocytes, and that
either one of these activities is expressed
under certain conditions of the host
animals.
The effect of 12S lymphocytes from
M-MuSV-induced sarcoma-bearing mice
was compared to that of antigenically
distinct tumour cells (MCA-15B). Neither
enhancement nor inhibition of tumour
was observed with MCA-15B cells. These
results, as well as the presence of neutral-
izing antibody against M-MuSV in the
serum ofmice inoculated with 12S lympho-
cytes, suggest some specificity in our
findings. Because of the lack of a suitable
control for the sarcoma virus, however,
we could not study the effect of 12S
lymphocytes against otherprimarytumour
systems. Therefore the question whether
the effect of 12S lymphocytes is specific
to the M-MuSV-induced tumour system or
is shared by other primary tumours is still
open.
We conclude that the inhibiting effect
of 128 lymphocytes was not due to the
presence of virus in the 12S lymphocytes
because, firstly, virus infection of these
lymphocytes was too low to induce such
an effect (whereas 104 FFU of virus was
required to show significant inhibition,
only 106 lymphocytes, which released no
more than 40 FFU of virus, manifested
significant inhibition). Secondly, the T-
cell-rich population, which was probably
the main effector population that pro-
duced the inhibiting effect, released a
lower amount of virus than the B-cell-rich
population, according to the infectious-
centre assay. Finally, preliminary experi-
ments showed that when 12S lymphocytes
(releasing 10-40 FFU ofvirus/I x 106 cells)
were irradiated, they failed to inhibit the
appearance oftumours. The earlier appear-
ance of virus-neutralizing antibody in
mice inoculated with 12S lymphocytes
suggests the participation of antibody
formation in the inhibiting effect. Pro-
duction of cytotoxic T lymphocytes speci-
fic to sarcoma cells may also be involved.
In the experiments into the mechanisms
of tumour-growth enhancement, the effect
of 12S lymphocytes was: (a) observable at
the first progressive stage of tumour
growth (Fig. 4A); (b) approximately
proportional to the numbers of inoculated
lymphocytes (Fig. 5B); (c) mediated
mainly by the T-cell population (Fig. 6B);
and (d) not observed against MCA-15B
cells (Fig. 7B). Taking these results into
consideration, possible explanations for
the mechanisms of enhancement included
in our discussion are: (i) non-specific
tumour enhancement, (ii) suppressor-cell
activity, and (iii) formation of blocking
factor.
(i) Non-specific tumour enhancement
This has been demonstrated in trans-
planted tumoursystems (Ilfeld et al., 1973;
Umiel and Trainin, 1974; Small and
Trainin, 1976; Gabizon et al., 1976).
Although the failure to enhance anti-
genically distinct syngeneic tumour cells
(MCA-15B) may imply that the mecha-
nism of enhancement in our system is a
specific one, it is possible that this failure
resulted from the nature of the tumour
cells. These cells were growing progres-
sively, and hence might have concealed an
enhancing effect. Actually, in some experi-
ments with fast-growing M-MuSV-induced
tumours in young mice, we failed to show
an enhancing effect on tumour growth. It
is unlikely, however, that a cell-free factor
released by 12S lymphocytes enhanced
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tumour growth, because culture medium,
collected from 12S lymphocytes and highly
concentrated, showed no enhancing effect
(unpublished observation).
Although the existence of a lymphocyte
population which inhibits tumour growth
in vivo has not yet been reported (Ilfeld
et al., 1973; Nordlund and Gershon, 1975),
in vitro evidence suggests the presence of
cytotoxic T cells and cytostatic B cells
in the M-MuSV system (Hellstrom and
Hellstr6m, 1969; Herberman et al., 1974;
Lamon et al., 1972; Plata et al., 1974;
Leclerc et al., 1972; Lamon et al., 1974;
Plata et al., 1976) and the regression of
tumours induced by regressor M-MuSV
has been attributed to the immune
response of the host animals (Fefer et al.,
1968; Weinert et al., 1974). In our experi-
mentswith progressorM-MuSV, the regres-
sive stage and the first plateau stage
observed in adult mice, as well as the
occasional regression of tumours, may
also be ascribed to the results of a host
immune response.
(ii) Suppressor-cell activity
Specific suppressor-cell activity of lym-
phocytes from tumour-bearing animals
has been reported in transplanted-tumour
systems (Fujimoto et al., 1976a, b). In the
M-MuSV system, suppressor-cell activity
of tumour-bearing spleen cells has been
reported in in vitro stimulation of lympho-
cytes (Kirchner et al., 1974; Gorczynski,
1974; Kirchner et al., 1975). In our system,
enhancement of tumour growth could
possibly be mediated by suppressor cells.
Afferent suppression of immune response
(inhibiting the production of cytotoxic or
antibody-forming lymphocytes) does not
seem to explain the enhancing effect of 128
lymphocytes, because these cells, when
inoculated before virus injection, demon-
strated an inhibiting effect. However, it is
possible that 12S lymphocytes do not
suppress antibody formation against the
sarcoma virus, but, instead, suppress the
production of cytotoxic lymphocytes.
Another possibility is that if 2 lymphocyte
subpopulations with conflicting activities
co-exist in the 12S lymphocytes (cytotoxic
killer cells and suppressor cells) suppressor
cells may lose their activity in the absence
of antigen stimulation (Fujimoto et al.,
1976b; Basten et al., 1975). Thus, when the
12S lymphocytes are inoculated before
the virus injection, the cytotoxic lympho-
cytes may dominate the suppressor cells
in the absence of antigen stimulation,
resulting in an inhibiting effect. On the
other hand, when the 12S lymphocytes are
inoculated after the virus injection, the
suppressor cells may dominate the cyto-
toxic cells in the presence of antigen
stimulation, resulting in an enhancing
effect.
Efferent suppression ofimmune response
(directly inhibiting the effect of immune
lymphocytes) may be another possibility.
Since 12S lymphocytes release virus,
although in small amounts, the 2 agents
possibly affecting immune response in this
way are virus and virus-producing cells.
Their effect was ruled out since the
inoculation of M-MuSV (103-105FFU/
mouse) or lymphoma cells (LSTRA, 105-
107 cells/mouse) did not enhance tumour
growth, even wheninoculated after tumour
development had begun.
(iii) Formation of blockingfactor
The induction of blocking factor by the
administration of 12S lymphocytes cannot
be excluded as a possibility. Enhanced
antibody formation induced by the inocu-
lation of 12S lymphocytes may account
for their enhancing activity. It is also
possible that antibody against 12S lym-
phocytes, elicited by their inoculation,
blocked the specific immune response
against tumour cells. Anti-idiotypic anti-
body formation has been reported in the
enhancement of renal allografts in rats
(McKearn et al., 1974; Stuart et al., 1976a,
1976b). Our preliminary experiments indi-
cated that X-irradiated 12S lymphocytes
similarly enhanced tumour growth in the
M-MuSV system. This finding suggests
that the lymphocytes which mediated the
enhancing effect were radiation-resistant,
or that they served as an antigen to elicit
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anti-idiotypic antibody in enhancing
mechanisms.
Whatever the mechanisms of the en-
hancing effect of 12S lymphocytes, their
elucidation will bring about a better
understanding of the reason why tumours
grow progressively in vivo in spite ofthe in
vitro evidence of immune response to the
tumour cells.
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